Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

11.20 -0.34 (-2.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 18,485,154
Open 11.86
Bid (Size) 11.21 (20)
Ask (Size) 11.30 (4)
Prev. Close 11.54
Today's Range 10.95 - 11.92
52wk Range 8.860 - 33.97
Shares Outstanding 128,395,927
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Final Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Reminds Aurinia Pharmaceuticals Inc. (AUPH) Investors of Class Action and Last Day to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
AURINIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Aurinia Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire

Performance

YTD
-50.18%
-50.18%
1 Month
-1.41%
-1.41%
3 Month
-10.04%
-10.04%
6 Month
-53.16%
-53.16%
1 Year
-22.44%
-22.44%

More News

Read More
AUPH FINAL DEADLINE TUESDAY: ROSEN, A LONGSTANDING LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important June 14 Deadline in Securities Class Action - AUPH
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
NASDAQ:AUPH Investor Notice: Deadline on June 14, 2022 in Lawsuit Against Aurinia Pharmaceuticals Inc.
Via SBWire
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
From Aurinia Pharmaceuticals Inc.
Via Business Wire
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
Via Benzinga
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AUPH
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Via Benzinga
Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
INVESTOR DEADLINE: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – AUPH
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Shareholder Action Reminder: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
PreMarket Prep Stock Of The Day: Good News From Aurinia Pharmaceuticals In A Down Week
Via Benzinga
77 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
103 Biggest Movers From Yesterday
Via Benzinga
Aurinia Reports First Quarter 2022 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Earnings Preview For Aurinia Pharmaceuticals
Via Benzinga
Shareholder Action Alert: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Investor Action Notice: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Investor Action Alert: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Shareholder Action Notice: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Shareholder Action Reminder: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.